Letybo 50IU (Single Vial)

Mode of action:

Clostridium botulinum neurotoxin type A blocks the peripheral release of the neurotransmitter acetylcholine at presynaptic cholinergic nerve terminals of neuromuscular junctions by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings, thereby leading to denervation of the muscle and a flaccid paralysis.

Contraindications:

-Hypersensitivity to the active substance or to any of the excipients.

-Generalised disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis).

-Presence of acute infection or inflammation at the proposed injection sites.